TipRanks financial accountability engine tracks the stock recommendations on over 8,000 different stocks and divides these stocks by sector. Using TipRanks’ Analysts’ Top Stocks tool we set out to discover the top stocks for each market sector. The Top Stocks tool selects stocks based on a TipRanks developed formula which factors in ratings made by the best-performing Street analysts- so this is a great way to find fresh investing inspiration.

Here, we filtered the options to strong buy stocks with a market cap of over $20 billion, and looked at each sector in turn. We sorted the stocks by upside potential- a crucial indicator for investors of the extent of the investing opportunity presented by that stock. TipRanks calculates the average analyst 12- month price targets on a stock from all the published  price targets. The upside (or in some cases the downside) is the difference between the current stock price and the price target.

By selecting the stock with the greatest upside potential for each sector we came up with the following list of 7 top stocks with the most analyst recommendations. The displayed results reveal all the crucial information on the stock including the analyst consensus rating, price target (in green), the stock price over the last three months and- interestingly- the reason why that stock has been included in the most recommended list (for example, if it receives a number of buy ratings from top-ranked analysts).

Stay updated on the stock by clicking the ‘follow’ button to receive real-time alerts of future ratings, or click the blue stock ticker for an in-depth analysis of the stock’s ratings.

Now let’s see what the most recommended stocks are (at the time of writing):

1. Tech- Crown Castle 

CCI: the US’s largest provider of wireless infrastructure. Wells Fargo’s Jennifer Fritzsche says CCI should benefit from an increase in carrier activity over other public tower companies given its large exposure to AT&T and domestic focus.

2. Healthcare- Amgen 

AMGN: the world’s largest independent biotech firm. Five-star Cowen & Co analyst Eric Schmidt says Amgen’s Repatha drug which treats high cholesterol could go on to have “blockbuster status”. FOURIER data on the drug from a cardiovascular outcomes trial is solid from both a clinical and commercial perspective says Schmidt.

3. Basic Materials- Devon Energy 

DVN: an independent natural gas and petroleum producer focused on onshore exploration and production in North America and Canada. Four-star BMO Capital analyst Phillip Jungwirth reiterated his buy rating on the stock on March 22 with a $50 price target (28% upside potential).

4. Consumer goods- Monster Beverage 

MNST: the international beverage company produces popular drinks such as Monster Energy and Hansen’s Natural Soda. Top Cowen & Co analyst Vivien Azer is very bullish on the company’s fast-expanding international presence with international net sales growth of 33% in 4Q16.

5. Services- Walgreens Boots Alliance 

WBA: one of the US’s largest pharmacy store chains. On March 27, four-star Robert W Baird analyst Eric Coldwell reiterated his WBA buy rating while predicting that the company’s approx. $7 billion buyout of Rite Aid will close at the beginning of August.

6. Industrial goods- Raytheon 

RTN: a major US defense contractor which manufactures weapons and electronics. In February, Raytheon won a foreign military sales (FMS) contract worth $1.07 billion from the US Air Force to provide an early warning radar system to the government of Qatar.

7. Financial- American Tower 

AMT: this diversified real estate investment trust (REIT) had “solid” Q4 results with “conservative” guidance according to top SunTrust analyst Gregory Miller who expects US growth to accelerate while foreign growth remains strong.